TriSalus Life Sciences
TLSI
26 hedge funds and large institutions have $9.03M invested in TriSalus Life Sciences in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
57% more capital invested
Capital invested by funds: $5.74M → $9.03M (+$3.29M)
37% more funds holding
Funds holding: 19 → 26 (+7)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.93% more ownership
Funds ownership: 2.57% → 3.51% (+0.93%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
+$2.92M |
| 2 |
Goldman Sachs
New York
|
+$503K |
| 3 |
BlackRock
New York
|
+$378K |
| 4 |
Millennium Management
New York
|
+$163K |
| 5 |
JP Morgan Chase
New York
|
+$97.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HC Advisors
Sandy Springs,
Georgia
|
-$860K |
| 2 |
HF
HRT Financial
New York
|
-$405K |
| 3 |
TWP
Tyche Wealth Partners
Plano,
Texas
|
-$154K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$152K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$137K |
TLSI Hedge Fund Activity: Q1 2024 in Review
26 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2024, worth a combined $9.03M — up 57% from $5.74M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TLSI positions and 3 closed out — a net gain of 7 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Duquesne Family Office, opening a new position worth an estimated $2.92M. The largest seller was HC Advisors, exiting entirely with an estimated $860K sold.
- 26 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2024, up from 19 in Q4 2023.
- Funds reported $9.03M of TriSalus Life Sciences stock for Q1 2024, up 57% quarter-over-quarter.
- 10 funds opened new TriSalus Life Sciences positions in Q1 2024 and 3 closed out, a net change of +7 holders.
- The largest TriSalus Life Sciences buyer in Q1 2024 was Duquesne Family Office, an estimated $2.92M added.
- The largest TriSalus Life Sciences seller in Q1 2024 was HC Advisors, an estimated $860K sold.
Based on aggregated 13F filings for Q1 2024.